期刊
JOURNAL OF MOLECULAR NEUROSCIENCE
卷 46, 期 3, 页码 569-577出版社
HUMANA PRESS INC
DOI: 10.1007/s12031-011-9644-x
关键词
AICD; Alzheimer's disease; Amyloid-precursor protein (APP); Histone-deacetylase (HDAC); Hippocampus; Cortex; Memory; Neprilysin; Novel object recognition test; Prenatal hypoxia; Valproic acid
资金
- U.K. MRC
- ARUK
- Russian Academy of Science
- RFBR [10-04-01156]
- MRC [G0802189] Funding Source: UKRI
- Medical Research Council [G0802189] Funding Source: researchfish
Alzheimer's disease (AD) is accompanied by memory loss due to neuronal cell death caused by toxic amyloid beta-peptide (A beta) aggregates. In the healthy brain, a group of amyloid-degrading enzymes including neprilysin (NEP) maintain A beta levels at physiologically low concentrations but, with age and under some pathological conditions, expression and activity of these enzymes decline predisposing to late-onset AD. Hence, up-regulation of NEP might be a viable strategy for prevention of A beta accumulation and development of the disease. As we have recently shown, inhibitors of histone deacetylases, in particular, valproic acid (VA), were capable of up-regulating NEP expression and activity in human neuroblastoma SH-SY5Y cell lines characterised by very low levels of NEP. In the present study, analysing the effect of i.p. injections of VA to rats, we have observed up-regulation of expression and activity of NEP in rat brain structures, in particular, in the hippocampus. This effect was brain region- and age-specific. Administration of VA has also restored NEP activity and memory deficit in adult rats caused by prenatal hypoxia. This suggests that VA and more specific HDAC inhibitors can be considered as potential pharmaceutical agents for up-regulation of NEP activity and improvement of cognitive functions of ageing brain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据